Equities

Singular Genomics Systems Inc

OMIC:NAQ

Singular Genomics Systems Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)16.26
  • Today's Change0.040 / 0.25%
  • Shares traded26.31k
  • 1 Year change+46.53%
  • Beta1.3885
Data delayed at least 15 minutes, as of Sep 20 2024 15:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform1
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Singular Genomics Systems Inc share price to fall to 6.50 in the next year from the last price of 16.22.
High-59.9%6.50
Med-59.9%6.50
Low-59.9%6.50

Earnings history & estimates in USD

On Aug 13, 2024, Singular Genomics Systems Inc reported 2nd quarter 2024 losses of -8.57 per share. This result was in line with the consensus of the 2 analysts following the company and exceeded last year's 2nd quarter results by 18.38%.
The next earnings announcement is expected on Nov 11, 2024.
Average growth rate+4.48%
Singular Genomics Systems Inc reported annual 2023 losses of -39.00 per share on Mar 18, 2024.
Average growth rate+18.74%
More ▼

Revenue history & estimates in USD

Singular Genomics Systems Inc had 2nd quarter 2024 revenues of 737.00k. This bettered the 400.00k estimate of the one analyst covering the company. This was 14.60% below the prior year's 2nd quarter results.
Average growth rate+33.27%
Singular Genomics Systems Inc had revenues for the full year 2023 of 2.91m. This was 280.52% above the prior year's results.
Average growth rate+280.52%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.